Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 3/2017

01-06-2017 | Kidney and Bone (S Moe and I Salusky, Section Editors)

Biomarkers Predicting Bone Turnover in the Setting of CKD

Authors: Pieter Evenepoel, Etienne Cavalier, Patrick C. D’Haese

Published in: Current Osteoporosis Reports | Issue 3/2017

Login to get access

Abstract

Purpose of the Review

Impaired bone quality contributes to the increased fracture risk in chronic kidney disease patients. Both low and high turnover bone disease may compromise bone quality. The question arises whether bone biomarkers may be additive or replace bone histormorphometry for diagnosing the extremes of bone turnover.

Recent Findings

Studies exploring the performance of established and emerging bone biomarkers against histomorphometric assessment of bone turnover are limited and overall yield inconclusive results as to their diagnostic utility.

Summary

Bone biomarkers, although promising, currently fail to meet the needed diagnostic accuracy to replace bone histomorphometry and thus are not yet ready for clinical use. Bone biomarkers have not only several advantages, but also important limitations such as high biological variability, retention with kidney disease, preanalytical issues, and interassay variability. These important issues must be considered when developing and evaluating bone biomarkers. There is an urgent need for harmonization and standardization of available assays and additional bone biopsy studies.
Literature
1.
Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2006;70:1358–66.CrossRefPubMed
2.
Ball AM, Gillen DL, Sherrard D, et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA. 2002;288:3014–8.CrossRefPubMed
3.
Tentori F, McCullough K, Kilpatrick RD, et al. High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int. 2014;85:166–73.CrossRefPubMed
4.
Naylor KL, McArthur E, Leslie WD, et al. The three-year incidence of fracture in chronic kidney disease. Kidney Int. 2014;86:810–8.CrossRefPubMed
5.
6.
Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res. 2011;26:1368–76.CrossRefPubMed
7.
•• Sprague SM, Bellorin-Font E, Jorgetti V, et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis. 2016;67:559–66. This KDIGO endorsed study examined the performance of a panel of bone biomarkers in diagnosing high and low bone turnover disease in a large cohort of hemodialysis patients. CrossRefPubMed
8.
•• Malluche HH, Porter DS, Monier-Faugere MC, Mawad H, Pienkowski D. Differences in bone quality in low- and high-turnover renal osteodystrophy. J Am Soc Nephrol. 2012;23:525–32. In-depth clinical investigation identifying mechanisms underlying impaired bone quality in patients with low- and high-turnover renal osteodystrophy. CrossRefPubMedPubMedCentral
9.
Torres PU, Bover J, Mazzaferro S, de Vernejoul MC, Cohen-Solal M. When, how, and why a bone biopsy should be performed in patients with chronic kidney disease. Semin Nephrol. 2014;34:612–25.CrossRefPubMed
10.
Frost ML, Compston JE, Goldsmith D, et al. (18)F-fluoride positron emission tomography measurements of regional bone formation in hemodialysis patients with suspected adynamic bone disease. Calcif Tissue Int. 2013;93:436–47.CrossRefPubMedPubMedCentral
11.
Naylor K, Eastell R. Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol. 2012;8:379–89.CrossRefPubMed
12.
Seeman E, Nguyen TV. Bone remodeling markers: so easy to measure, so difficult to interpret. Osteoporos Int. 2016;27:33–5.CrossRefPubMed
13.
Amling M, Herden S, Posl M, Hahn M, Ritzel H, Delling G. Heterogeneity of the skeleton: comparison of the trabecular microarchitecture of the spine, the iliac crest, the femur, and the calcaneus. J Bone Miner Res. 1996;11:36–45.CrossRefPubMed
14.
Cavalier E, Delanaye P, Moranne O. Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: implications for clinical decision making. Am J Kidney Dis. 2013;61:847–8.CrossRefPubMed
15.
Sardiwal S, Gardham C, Coleman AE, Stevens PE, Delaney MP, Lamb EJ. Bone-specific alkaline phosphatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients. Kidney Int. 2012;82:100–5.CrossRefPubMedPubMedCentral
16.
Chavassieux P, Portero-Muzy N, Roux JP, Garnero P, Chapurlat R. Are biochemical markers of bone turnover representative of bone histomorphometry in 370 postmenopausal women? J Clin Endocrinol Metab. 2015;100:4662–8.CrossRefPubMed
17.
de Oliveira RA, Barreto FC, Mendes M, et al. Peritoneal dialysis per se is a risk factor for sclerostin-associated adynamic bone disease. Kidney Int. 2015;87:1039–45.CrossRefPubMed
18.
Haarhaus M, Monier-Faugere MC, Magnusson P, Malluche HH. Bone alkaline phosphatase isoforms in hemodialysis patients with low versus non-low bone turnover: a diagnostic test study. Am J Kidney Dis. 2015;66:99–105.CrossRefPubMedPubMedCentral
19.
20.
Barreto FC, Barreto DV, Moyses RMA, et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int. 2008;73:771–7.CrossRefPubMed
21.
Lehmann G, Stein G, Huller M, Schemer R, Ramakrishnan K, Goodman WG. Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int. 2005;68:1206–14.CrossRefPubMed
22.
Bervoets AR, Spasovski GB, Behets GJ, et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis. 2003;41:997–1007.CrossRefPubMed
23.
Couttenye MM, D’Haese PC, Van Hoof VO, et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant. 1996;11:1065–72.CrossRefPubMed
24.
Monier-Faugere MC, Geng Z, Mawad H, et al. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int. 2001;60:1460–8.CrossRefPubMed
25.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1–S130.
26.
Evenepoel P, Bover J, Torres P. Parathyroid hormone metabolism and signaling in health and chronic kidney disease. Kidney Int 2016;90:1184–90.
27.
Herberth J, Branscum AJ, Mawad H, Cantor T, Monier-Faugere MC, Malluche HH. Intact PTH combined with the PTH ratio for diagnosis of bone turnover in dialysis patients: a diagnostic test study. Am J Kidney Dis. 2010;55:897–906.CrossRefPubMedPubMedCentral
28.
Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19:179–92.CrossRefPubMed
29.
Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol. 2013;8:819–23.CrossRefPubMedPubMedCentral
30.
Piec I, Washbourne C, Tang J, et al. How accurate is your sclerostin measurement? Comparison between three commercially available sclerostin ELISA kits. Calcif Tissue Int. 2016;98:546–55.CrossRefPubMedPubMedCentral
31.
Mause SF, Deck A, Hennies M, et al. Validation of commercially available ELISAs for the detection of circulating sclerostin in hemodialysis patients. Discoveries (Craiova ). 2016;4:e55.CrossRef
32.
Cavalier E, Lukas P, Carlisi A, Gadisseur R, Delanaye P. Aminoterminal propeptide of type I procollagen (PINP) in chronic kidney disease patients: the assay matters. Clin Chim Acta. 2013;425:117–8.CrossRefPubMed
33.
Yamada S, Inaba M, Kurajoh M, et al. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Clin Endocrinol. 2008;69:189–96.CrossRef
34.
Cavalier E, Souberbielle JC, Gadisseur R, Dubois B, Krzesinski JM, Delanaye P. Inter-method variability in bone alkaline phosphatase measurement: clinical impact on the management of dialysis patients. Clin Biochem. 2014;47:1227–30.CrossRefPubMed
35.
Lehmann G, Ott U, Kaemmerer D, Schuetze J, Wolf G. Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease stages 3-5. Clin Nephrol. 2008;70:296–305.CrossRefPubMed
36.
Urena P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol. 1996;7:506–12.PubMed
37.
Urena P, de Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int. 1999;55:2141–56.CrossRefPubMed
38.
Coen G, Ballanti P, Bonucci E, et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant. 1998;13:2294–302.CrossRefPubMed
39.
Urena P, Ferreira A, Kung VT, et al. Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. J Bone Miner Res. 1995;10:932–9.CrossRefPubMed
40.
Bjarnason NH, Henriksen EE, Alexandersen P, Christgau S, Henriksen DB, Christiansen C. Mechanism of circadian variation in bone resorption. Bone. 2002;30:307–13.CrossRefPubMed
41.
Franke S, Lehmann G, Abendroth K, Hein G, Stein G. PICP as bone formation and NTx as bone resorption marker in patients with chronic renal failure. Eur J Med Res. 1998;3:81–8.PubMed
42.
Shidara K, Inaba M, Okuno S, et al. Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. Calcif Tissue Int. 2008;82:278–87.CrossRefPubMed
43.
Wu Y, Lee JW, Uy L, et al. Tartrate-resistant acid phosphatase (TRACP 5b): a biomarker of bone resorption rate in support of drug development: modification, validation and application of the BoneTRAP kit assay. J Pharm Biomed Anal. 2009;49:1203–12.CrossRefPubMed
44.
Chu P, Chao TY, Lin YF, Janckila AJ, Yam LT. Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am J Kidney Dis. 2003;41:1052–9.CrossRefPubMed
45.
Malluche HH, Davenport DL, Cantor T, Monier-Faugere MC. Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis. Clin J Am Soc Nephrol. 2014;9:1254–62.CrossRefPubMedPubMedCentral
46.
Ueda M, Inaba M, Okuno S, et al. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis. 2002;40:802–9.CrossRefPubMed
47.
Maeno Y, Inaba M, Okuno S, Yamakawa T, Ishimura E, Nishizawa Y. Serum concentrations of cross-linked N-telopeptides of type I collagen: new marker for bone resorption in hemodialysis patients. Clin Chem. 2005;51:2312–7.CrossRefPubMed
48.
Fishbane S, Hazzan AD, Jhaveri KD, Ma L, Lacson E Jr. Bone parameters and risk of hip and femur fractures in patients on hemodialysis. Clin J Am Soc Nephrol 2016;11:1063–72.
49.
Perrin P, Caillard S, Javier RM, et al. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am J Transplant. 2013;13:2653–63.CrossRefPubMed
50.
Yamada S, Tsuruya K, Yoshida H, et al. The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis. Clin Endocrinol. 2013;78:844–51.CrossRef
Metadata
Title
Biomarkers Predicting Bone Turnover in the Setting of CKD
Authors
Pieter Evenepoel
Etienne Cavalier
Patrick C. D’Haese
Publication date
01-06-2017
Publisher
Springer US
Published in
Current Osteoporosis Reports / Issue 3/2017
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-017-0362-3

Other articles of this Issue 3/2017

Current Osteoporosis Reports 3/2017 Go to the issue

Muscle and Bone (L Bonewald and M Hamrick, Section Editors)

The Role of the Molecular Clock in Skeletal Muscle and What It Is Teaching Us About Muscle-Bone Crosstalk

Osteoimmunology (M Nakamura and M Humphrey, Section Editors)

TNF and Bone Remodeling

Kidney and Bone (S Moe and I Salusky, Section Editors)

Renal Osteodystrophy or Kidney-Induced Osteoporosis?

Kidney and Bone (S Moe and I Salusky, Section Editors)

Treatment of Pediatric Chronic Kidney Disease-Mineral and Bone Disorder

Rare Bone Diseases (C Langman and E Shore, Section Editors)

Hereditary Multiple Exostoses: New Insights into Pathogenesis, Clinical Complications, and Potential Treatments

Osteoimmunology (M Nakamura and M Humphrey, Section Editors)

Parathyroid Diseases and T Cells